Indication intelligence, analysis and sector perception

Sage Therapeutics (SAGE) Restructuring

April 7, 2020 9:29pm

RIF of 340 employees, 53% of workforce

Sage closed up +$0.66 to $29.03 and is up in the aftermarket +$0.31 or +1.07%

Based on the current operating plan and assumptions, SAGE’s balance of cash assets (approximately) $1 billion at the end of 2019 will support its “runway” into 2022. SAGE expects to incur a one-time cost of approximately $31 million, associated with the reduction in workforce, primarily in Q2/2020

SAGE announced a restructuring intended to enable it to cost save anticipating an annualized savings of approximately $170 million, of which $150 million is related to SG&A.

The workforce reduction will primarily affect the ZULRESSO™ (brexanolone) CIV injection commercial operation and related SG&A support functions.

SAGE remains committed ZULRESSO, but commercial efforts will be focused on geographies that have existing, active ZULRESSO treating sites.

SAGE continues to focus on its three (3) brain health franchises – depression, neurology and neuropsychiatry – and anticipated 2020 and 2021 R&D milestones remain unchanged.

The Bottom line: it’s a tough, harsh but a strategic move in these tough times however it is just the first of many companies who will be forced to explore their alternatives … guidance will be provided in Q1/2020 quarterly earnings update in May.

Many will consider this an excuse ... although “Zulresso is a hospital-based treatment, so we are in competition for beds with COVID-19”.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

4 hours 56 min ago
RegMed Investors’ (RMi) pre-open: market, market and the sector pullbacks are driven by Israel retaliation against Iran tempered expectations for a rate cut

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.